France-based start-up Previa Medical says it has raised €2.1 million in seed funding for SEPSI-SCORE, a specialist AI-based solution designed to improve the early detection of sepsis in healthcare facilities.
The funding will be used to initiate a trial of SEPSI-SCORE solution in hospital settings, demonstrating platform's potential to reduce length of inpatient stays and increase patient survival rates. Previa Medical is a deeptech start-up specialising in developing predictive medical devices for alerting healthcare providers to the risk of potential complications.
The SEPSI-SCORE platform, which gained medical device certification in 2021, can alert healthcare professionals to potential sepsis cases - up to 48 hours prior to the development of first symptoms. The platform analyses data directly from existing software in hospitals, in real time, from the electronic health records of patients, including their laboratory results, vital signs and medical history. As this enables healthcare professionals to accurately identify patients at risk, the required treatment can be administered as soon as possible, thereby increasing the chances of patient survival.
Sepsis is one of the leading causes of hospital deaths worldwide, with a 30-day mortality rate of 20 to 30%. SEPSI-SCORE therefore provides a much-needed solution to a major global public health issue.
“We’re delighted to have secured this financial backing from our investors, a testament to their belief in our technology. We are confident that through their business development experience, technical expertise and network in the healthcare sector, we’ll be able to take our business to the next level,” said Quentin François, co-founder and CEO of Previa Medical.